Regentis Biomaterials Ltd. (NYSE American: RGNT) is seeking to redefine knee cartilage repair with its resorbable hydrogel technology, GelrinC, according to a recent BioMedNewsBreaks report. The acellular implant is designed to shift treatment from symptom management toward early structural repair, potentially offering a more durable solution than current standards of care.
Unlike microfracture, which often produces less-durable fibrocartilage, GelrinC is engineered to gradually resorb as surrounding cells regenerate hyaline-like cartilage. This approach avoids cell harvesting and a second surgery, which could reduce patient burden and healthcare costs. In a Phase II study, Regentis reported roughly 100% greater KOOS improvement versus microfracture at 24 months, along with a mean MOCART score of 88.8/100, indicating strong structural repair.
GelrinC has already received CE Mark approval in Europe, and a pivotal U.S. trial is targeting completion around year-end 2026. Longer-term development programs are aimed at smaller-joint defects and moderate osteoarthritis, positioning Regentis around the broader orthopedic trend toward earlier intervention and durable tissue preservation rather than waiting for disease progression. The company estimates a market of approximately 470,000 cartilage knee repair cases annually in the U.S. where no off-the-shelf treatment is available.
For investors, the progress of GelrinC could represent a significant opportunity in the regenerative medicine space. Regentis Biomaterials (NYSE American: RGNT) is dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. The lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. To view the full article, visit https://ibn.fm/DjPC4.
The announcement was disseminated through BioMedWire, a specialized communications platform focused on the latest developments in biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BioMedWire is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public.
For more information, please visit BioMedWire. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer. The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT.
